key: cord-0735256-k50qvr4w
authors: Pani, Arianna; Lauriola, Marinella; Romandini, Alessandra; Scaglione, Francesco
title: Macrolides and viral infections: focus on azithromycin in COVID-19 pathology
date: 2020-06-10
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106053
sha: f903cb1e0462f453cf6189b43ad8eaf7c7fc1145
doc_id: 735256
cord_uid: k50qvr4w

The emergence of the new disease COVID-19, is posing the challenge of seeking effective therapies. Since the most severe clinical manifestation of COVID-19 appeared to be a severe acute respiratory syndrome, azithromycin has been proposed as a potential treatment. Azithromycin is known to have immunomodulating and antiviral properties. In vitro studies have demonstrated the capacity of azithromycin to reduce production of pro-inflammatory cytokines such as IL-8, IL-6, TNF alpha, reduce oxidative stress and modulate T-helper functions. At the same time there are multiple clinical evidences of the role of azithromycin in acute respiratory distress syndrome and against MERS. Some preliminary evidences have demonstrated controversial results regarding efficacy of azithromycin in combination with hydroxychloroquine in COVID-19. Firstly, a French trial demonstrated 100% of virological negativization of six patients treated with azithromycin plus hydroxychloroquine vs 57.1% of patients treated with only hydroxychloroquine and 12.5% of the control group (p<0.05). On the other hand, another case series revealed no efficacy at all on eleven patients treated with same combination and doses. Furthermore, there are some concerns regarding the association of azithromycin and hydroxychloroquine because of the potential Qt prolongation. In fact, both drugs have this as potential side effect and evidences regarding the safety use of this combination are controversial. Despite the necessity to quickly find solutions for COVID-19, extreme caution must be used in evaluating the risk-benefit balance. However, based on preclinical and clinical evidences and some preliminary results in COVID-19, azithromycin could have a potential in the fight against this new disease.

French trial demonstrated 100% of virological negativization of six patients treated with azithromycin plus hydroxychloroquine vs 57.1% of patients treated with only hydroxychloroquine and 12.5% of the control group (p<0.05). On the other hand, another case series revealed no efficacy at all on eleven patients treated with same combination and doses.

Furthermore, there are some concerns regarding the association of azithromycin and hydroxychloroquine because of the potential Qt prolongation. In fact, both drugs have this as potential side effect and evidences regarding the safety use of this combination are controversial.

Despite the necessity to quickly find solutions for COVID-19, extreme caution must be used in evaluating the risk-benefit balance. However, based on preclinical and clinical evidences and some preliminary results in COVID-19, azithromycin could have a potential in the fight against this new disease. Gram-positive and atypical bacterial species that are commonly associated with respiratory 4 tract infections. In addition to their antibacterial effects, macrolides have been shown to 5 have immunomodulatory and anti-inflammatory effects [1] [2] [3] . The severity and mortality 6 caused of respiratory viral infections including COVID-19 is associated with the host's 7 excessive inflammatory response characterized by hyper-production of cytokines [4] [5] [6] . 8 Preclinical and clinical studies have shown that macrolides regulate the inflammatory 9 response, attenuating the production of anti-inflammatory cytokines and also promoting 10 the production of immunoglobulins [7] . These regulatory effects on immune response 11 reduce complications of respiratory viral infections [8] [9] [10] . Due to these 12 immunomodulating properties, macrolides (eg. azithromycin, clarithromycin, 13 erythromycin, fidaxomycin) have been studied extensively for their potential use as 14 adjunctive broad spectrum therapy for viral respiratory infections including influenza 15 [7, [10] [11] [12] [13] . 16 In this narrative review we will explore the role of macrolides in COVID-19 17 pathology, focusing on azithromycin, considering it the most suitable macrolide in a 18 possible therapeutic combination. 19 We thus performed a literature search of MEDLINE with the following search terms 20 "azithromycin and viral infections", "azithromycin and SARS-CoV2", "azithromycin and 21 COVID-19", "azithromycin and Qt prolongation", "azithromycin and chloroquine and Qt 22 prolongation". We have selected most updated evidences and all those relevant to 23 synthesize the role of macrolides in COVID-19 treatment. 26 Clarithromycin, azithromycin, erythromycin, bafilomycin A1 and telithromycin have 27 shown to have anti-inflammatory and immunomodulatory effects [10] . For this reason, 28 macrolides have been proposed as options for viral respiratory infections presenting an 29 inflammatory basis, including COVID-19. Immunomodulating activities of azithromycin 30 are explicated in two different moment of the disease, during the acute phase and at the 31 resolution of the chronic inflammation. In the acute phase, the ability of azithromycin to reduce the production of pro-inflammatory cytokines such as IL-8, IL-6, TNF alpha, MMPs 33 is thoroughly demonstrated [14] . In the resolution phase, this macrolide has been shown 34 to increase neutrophil apoptosis and the oxidative stress related with inflammation. Also, 35 clarithromycin, Bafilomycin A1 and Erythromycin has been found to inhibit the production of the 36 intercellular adhesion molecule (ICAM)-1 and IL-1β, IL-6, IL-8 and TNF-α in rhinovirus and influenza 37 infection models [11, [15] [16] [17] . Furthermore, in a study conducted by Murphy et al, azithromycin 38 was associated with a shift of the T-helper phenotype from type I to type II, favoring 39 tissue repair after the inflammation. Moreover, azithromycin attenuates the effects of 40 lipopolysaccharide on lung allograft bronchial epithelial cells [11, [18] [19] [20] [21] [22] . 41 In addition, this drug is able to significantly reduce the expression of iNOS and the The association of azithromycin with QTc prolongation is controversial and still debated. 

Anti-inflammatory effects of macrolides--an underappreciated